July’s edition of Small Molecules of the Month, features a selective monovalent estrogen receptor degrader in Ph. III, a remarkable 4(!) neurology clinical candidates from Takeda (including 2 recently licensed by Takeda to Neurocrine, TAK-653 and TAK-041), several oncology clinical candidates including two sulfoximines, and a small molecule that degrades its target via its own ubiquitination.
Thanks to our featured reviewers for their feedback, with special thanks to neuroscience reviewer Jake Schwarz for feedback and commentary on an unusual 5 neuroscience molecules this month.
A slide deck with more details about each molecule is available.
Work smarter in two minutes. Join >4,000 drug hunters from every major biopharma company in the world getting drug discovery updates through our Drug Hunter e-mail newsletter. Unsubscribe anytime.
